HER2+ breast cancer usually grows aggressively, and HER2-targeted antibody therapy using pertuzumab/trastuzumab plus a taxane has been widely used as the first-line standard therapy in HER2-enriched BC patients [5]. The gene discussed is ERBB2; the disease is breast carcinoma.